Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248531 | 0.95 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL5739981 | 0.83 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL5739138 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL5738713 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL5739237 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL5740313 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL5739863 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL4244997 | 0.76 | HTR1A (0.48) | HTR1A | |
| SCHEMBL9380400 | 0.71 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL5745908 | 0.71 | HTR1A (0.52) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| CN-101087610-A | Arylpiperazine derivatives and their use as 5-HT1AUse of receptor ligands | SCHWARZ PHARMA S L (ES) | 2007-12-12 | — | — | CN | disclosed |
| EP-1830854-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | Schwarz Pharma, s.l. (ES) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006069993-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | SCHWARZ PHARMA S.L. (ES) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | SMN1; SMN2 1400/4885ALDH1A1 671/4885LMNA 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.